🔗 Share this article

Elected officials have issued warnings that the United Kingdom's negotiated accords with the US administration are "lacking a solid foundation." This stems from revelations that a recently announced deal on drug pricing, which commits to zero tariffs in exchange for the NHS paying more, lacks any formal legal text beyond limited headline terms outlined by government press releases.

An Agreement in Principle Only

The deal on drug tariffs, hailed as a "generational" achievement, exists as an "broad understanding" without formal ratification. Critics have noted that the official announcements from the UK and US governments frame the deal in markedly contrasting terms. The British version focuses on securing "duty-free access" as a singular success, while the American announcement dwells on the agreement for the NHS to pay 25% more for new medications.

"There is a serious risk that the UK government has promised concessions to increase medicine costs in return for nothing more than a assurance from President Trump," commented David Henig, a trade policy analyst. "History shows he has a tendency for not honouring his word."

Broader Instability and a Paused Tech Deal

Concerns have been heightened by Washington's action to suspend the major technology agreement, which was previously called "a generational step-change" in the bilateral relationship. The US claimed a lack of progress from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions secured for British farmers as part of an initial accord have yet to be formally ratified by the US, despite a looming January deadline. "We have been informed that that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Anxiety Behind Closed Doors

Behind the scenes, ministers have admitted unease that the government's agreements with the US are lacking substance. One minister reportedly said the series of agreements as "resting on shaky ground," while another characterized the situation as the "prevailing condition" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, stated: "Perhaps most shocking than Trump's temper tantrums is the UK government's credulous faith that his administration is a reliable partner. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Government figures have downplayed the risk of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been lobbying for the agreement, wanting clarity on imports and pricing, making it less abstract than the paused tech deal.

Officials acknowledge that unpredictability is part and parcel of dealing with the current US leadership. However, they argue that the UK has secured concrete outcomes for businesses, such as lower steel tariffs compared to other nations. "Securing 25% steel tariffs, which is better than the rate for the rest of the world, is a solid gain," one official said.

However, problems have arisen in implementing the May tariff agreement. Promised quotas on beef exports have failed to be approved, and the assurance to "reduce steel tariffs to zero" has is still pending, with tariffs fixed at 25%.

As negotiations continue, the two sides have planned to recommence talks on the paused tech prosperity deal in January, following what were described as "productive" meetings between UK and US officials in Washington.